NONPROFIT, NONPARTISAN PLATFORM OF ACCURATE SCIENCE-BASED SOLUTIONS TO COVID-19

Becton Dickinson

Business Name:
Becton Dickinson
Business Genre:
Business Description:

A global medical technology company that is focusing on advancing medical discovery, diagnostics, and delivery of care. [1]

City:
Franklin Lakes
State:
NJ
Country:
USA
Data/Evidence of Effectiveness:
Low positive sample showed 95% positive agreement, while moderate positive sample showed 100% positive agreement. Negative samples showed 100% negative agreement. [4]
Complimentary Products Needed to Perform Test:
BD MAX System and BD UVT Collection Kit [4]
Setting of Care:
Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform moderate and high complexity tests. [2]
Current Status / Clinical Development Stage / Expected Milestones:
EUA approval and available for sale [2]
LOD:
40 [4]
Funding & Ownership :
Delisted [5], Cap: 72.814 B [6]
Business Model:
The company provides various products in medical research, diagnosis of infectious disease and cancer, equip surgical and interventional procedures and support the management of diabetes. [1]
IP:
BD Max system is registered as a trademark [7]
History & Origins :
BD is a global company that focuing on medical innovation and clinical excellence. They provided products in numerous area of diagnosis of infectious diseases and cancer. [1]
Date EUA Issued:
04/08/2020 [2]
Sources:
“[1] https://www.bd.com/en-us/company [2] https://www.fda.gov/media/136813/download [3] https://www.bd.com/en-us/offerings/capabilities/molecular-diagnostics/molecular-tests/biogx-sars-cov-2-reagents [4] https://www.fda.gov/media/136816/download [5] https://www.crunchbase.com/organization/becton-dickinson#section-overview [6] https://finance.yahoo.com/quote/BDX?p=BDX&.tsrc=fin-srch [7] https://www.bd.com/en-us/offerings/capabilities/molecular-diagnostics/molecular-systems/bd-max-system [8] https://www.bd.com/en-us/company/executive-leadership”
Organization:
Simon Campion, Gary Cohen, Alexandre Conroy, John Deford, Tony Ezell, Jerry Flasz (Executive Vice President) [8]
No. Tests Per Day:
assume prep time + run time 3 hrs for every 96 samples, ~800 / day
Time to Result:
No information
Test Sample Type:
Nasal, nasopharyngeal and oropharyngeal swab [2]
Technology Overview:
Paired with the BD MAX system, after loading the samples to the buffer tube, all the following steps of nucleuic acid extraction and PCR are done automatically. Detect 2 region of the N genes. Human RNase P gene amplifcation serve as internal control. [4]
Testing Type:
Real-time RT-PCR test using the BD MAX System [3][4]
Test Category:
RT-PCR
Test Name:
BioGX SARS-CoV-2 Reagents for BD MAX™ System [3]
Clinical Application & Need:
Qualitative test for the detection of nucleic acid from SARS-CoV-2 [2]
Age of Company:
1897

Send Message to listing owner